Wockhardt Limited — Updates, 29-05-2025: Press Release

Wockhardt’s FY25 revenue rose 5% to INR 3,033 Cr, with a 67% jump in EBITDA to INR 418 Cr, driven by strong operations. The launch of MIQNAF, India’s first indigenous respiratory antibiotic for resistant pneumonia, targets a significant market gap. ZAYNICH® showed better Phase III results, filed in India and planned for the US, while WCK 6777 gained FDA Fast Track status. Biosimilars and international markets, particularly the UK and Ireland, maintain steady growth momentum.